Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03152487 · ClinicalTrials.gov registry record · NA

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis

A NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by AdventHealth.

Completed
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT03152487 is a NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma that has completed, run by AdventHealth. The registered enrollment target is 28 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03152487, a NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, has completed, sponsored by AdventHealth.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

Pancreatic cancer is the second most common gastrointestinal malignancy. Abdominal discomfort is a main symptom in patients with pancreatic cancer. Approximately 75% have pain at diagnosis and over 90% in advanced stages. Pain control is an important part of the plan of care for patients with pancreatic cancer.. The celiac plexus is a group of nerves that supply organs in the abdomen. EUS-guided celiac plexus neurolysis (EUS-CPN) has been widely used for pain management in patients with pancreatic cancer. Radiofrequency ablation of celiac ganglia or celiac plexus (EUS-RFA) is also being performed to alleviate abdominal pain in pancreatic cancer patients. However currently no comparative studies exist comparing EUS-CPN with EUS-RFA. The purpose of the study is to compare EUS-CPN with EUS-RFA for pain management in pancreatic patients, in order to determine which technique is better at improving pain in pancreatic cancer patients.

Interventions

  • OTHER Celiac Plexus Neurolysis
  • OTHER Radiofrequency Ablation

Study Locations (1)

Florida

  • Center for Interventional Endoscopy - Florida Hospital - Orlando

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2017-04-24
Est. Completion 2018-08-01
Phase NA

Sponsor

AdventHealth

95 total trials

What the Registry Record Tells You About NCT03152487

The ClinicalTrials.gov registry entry for NCT03152487 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is AdventHealth, which has 95 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Celiac Plexus Neurolysis is the first listed.

NCT03152487 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03152487 about?

NCT03152487 is a clinical study titled "Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis". Pancreatic cancer is the second most common gastrointestinal malignancy. Abdominal discomfort is a main symptom in patients with pancreatic cancer. Approximately 75% have pain at diagnosis and over 90% in advanced stages. Pain control is an important part of the plan of care for patients with pancre...

What is the current status of trial NCT03152487?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2017-04-24. Estimated completion is 2018-08-01.

What conditions does trial NCT03152487 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer, Adult, Pancreatic Carcinoma Metastatic.

What interventions are being tested in trial NCT03152487?

The interventions under investigation include: Celiac Plexus Neurolysis (OTHER), Radiofrequency Ablation (OTHER).

Who is sponsoring clinical trial NCT03152487?

This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03152487 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.